These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32322662)

  • 21. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
    Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
    Deng L; Fan J; Guo M; Huang B
    Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
    Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
    Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor.
    Tähtinen S; Grönberg-Vähä-Koskela S; Lumen D; Merisalo-Soikkeli M; Siurala M; Airaksinen AJ; Vähä-Koskela M; Hemminki A
    Cancer Immunol Res; 2015 Aug; 3(8):915-25. PubMed ID: 25977260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus.
    Hirvinen M; Rajecki M; Kapanen M; Parviainen S; Rouvinen-Lagerström N; Diaconu I; Nokisalmi P; Tenhunen M; Hemminki A; Cerullo V
    Hum Gene Ther; 2015 Mar; 26(3):134-44. PubMed ID: 25557131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cellular Virotherapy Increases Tumor-Infiltrating Lymphocytes (TIL) and Decreases their PD-1
    Morales-Molina A; Rodríguez-Milla MÁ; Gimenez-Sanchez A; Perisé-Barrios AJ; García-Castro J
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncolytic Adenovirus in Cancer Immunotherapy.
    Peter M; Kühnel F
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33202717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of the tumor microenvironment with an oncolytic adenovirus for effective T-cell therapy and checkpoint inhibition.
    Santos JM; Havunen R; Hemminki A
    Methods Enzymol; 2020; 635():205-230. PubMed ID: 32122546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
    Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
    Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncolytic Adenovirus: Prospects for Cancer Immunotherapy.
    Zhao Y; Liu Z; Li L; Wu J; Zhang H; Zhang H; Lei T; Xu B
    Front Microbiol; 2021; 12():707290. PubMed ID: 34367111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment.
    Rosewell Shaw A; Suzuki M
    Front Immunol; 2018; 9():2103. PubMed ID: 30298067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity.
    Yan Y; Li S; Jia T; Du X; Xu Y; Zhao Y; Li L; Liang K; Liang W; Sun H; Li R
    Tumour Biol; 2015 Jun; 36(6):4535-43. PubMed ID: 25627006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
    Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
    Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The emerging role of oncolytic virus therapy against cancer.
    Russell L; Peng KW
    Chin Clin Oncol; 2018 Apr; 7(2):16. PubMed ID: 29764161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
    Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
    Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
    Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
    Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.
    Hemminki O; Parviainen S; Juhila J; Turkki R; Linder N; Lundin J; Kankainen M; Ristimäki A; Koski A; Liikanen I; Oksanen M; Nettelbeck DM; Kairemo K; Partanen K; Joensuu T; Kanerva A; Hemminki A
    Oncotarget; 2015 Feb; 6(6):4467-81. PubMed ID: 25714011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model.
    Rincón E; Cejalvo T; Kanojia D; Alfranca A; Rodríguez-Milla MÁ; Gil Hoyos RA; Han Y; Zhang L; Alemany R; Lesniak MS; García-Castro J
    Oncotarget; 2017 Jul; 8(28):45415-45431. PubMed ID: 28525366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraperitoneal oncolytic and tumor vaccination therapy with replication-competent recombinant virus: the herpes paradigm.
    Coukos G; Courreges MC; Benencia F
    Curr Gene Ther; 2003 Apr; 3(2):113-25. PubMed ID: 12653405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.